Common Drug Side Effects & Monitoring (MRCP Part 1)

Crack Medicine
Jan 18
3 min read

TL;DR

In MRCP Part 1, questions on drugs reward candidates who recognise common adverse effects and know what to monitor—not those who memorise exhaustive lists. Focus on classic drug–side effect–investigation pairings such as ACE inhibitors with potassium and creatinine, or lithium with thyroid and renal function. This article summarises the examinable scope, high-yield patterns, common traps, and a practical checklist to secure easy marks.

Why this matters

Drug side effects and monitoring are among the most reliable scoring areas in MRCP Part 1. They appear across multiple specialties—cardiology, psychiatry, endocrinology, infectious diseases—and are often tested through short, data-driven vignettes. A candidate who recognises the pattern can answer in seconds; one who hesitates over rare adverse effects usually loses time and marks.

The exam deliberately avoids obscure pharmacology. Instead, it tests whether you can practise safe medicine: spotting predictable toxicity, knowing baseline tests, and identifying when treatment should be adjusted rather than stopped. This makes the topic ideal for repeated revision alongside question practice from the MRCP Part 1 overview and targeted MCQs.

What MRCP Part 1 expects you to know

The College’s written papers emphasise:

Common adverse effects that influence management
Serious toxicities you must not miss
Routine monitoring tests before and after starting therapy
Drug–disease contraindications
Class effects, not rare idiosyncratic reactions

Exact monitoring intervals are rarely tested. Knowing what to check is far more important than how often.

High-yield drug classes and monitoring points

The following numbered list covers drug groups that recur consistently in MRCP Part 1 questions.

ACE inhibitors and ARBs Adverse effects: Hyperkalaemia, rise in creatinine, cough (ACE inhibitors).Monitoring: Urea and electrolytes before and after initiation.
Loop and thiazide diuretics Adverse effects: Hypokalaemia (both), hyponatraemia and hyperuricaemia (thiazides).Monitoring: Electrolytes; think gout in susceptible patients.
Beta-blockers Adverse effects: Bradycardia, fatigue, bronchospasm (non-selective agents).Monitoring: Heart rate and contraindications such as asthma or heart block.
Calcium channel blockers Adverse effects: Ankle oedema (dihydropyridines), constipation and bradycardia (verapamil).Monitoring: Pulse with rate-limiting drugs.
Statins Adverse effects: Myalgia, rare rhabdomyolysis, transaminitis. Monitoring: Baseline liver function tests; CK only if symptomatic.
Warfarin Adverse effects: Bleeding, skin necrosis (rare).Monitoring: INR and drug interactions.
Direct oral anticoagulants (DOACs)Adverse effects: Bleeding. Monitoring: Renal function for dosing.
Lithium Adverse effects: Tremor, hypothyroidism, nephrogenic diabetes insipidus. Monitoring: Lithium levels, renal function, thyroid function tests.
Antipsychotics Adverse effects: Extrapyramidal symptoms (typical), metabolic syndrome and QT prolongation (atypical).Monitoring: Weight, glucose, lipids; ECG in selected patients.
Methotrexate Adverse effects: Bone marrow suppression, hepatotoxicity, pneumonitis. Monitoring: Full blood count and liver function tests; folic acid co-prescription.

MRCP Part 1 candidate revising drug side effects and monitoring with notes and laptop

Five most tested subtopics

Electrolyte disturbances (ACE inhibitors, diuretics, spironolactone)
Renal toxicity and dose adjustment (lithium, DOACs)
QT prolongation and arrhythmia risk (antipsychotics, macrolides)
Muscle and liver toxicity (statins, antiepileptics)
Bone marrow suppression (methotrexate, carbimazole)

Five classic exam traps

Ordering the wrong monitoring test (routine CK for statins without symptoms).
Stopping a drug prematurely when a mild, expected lab change is described.
Missing class effects and focusing on individual brand names.
Ignoring renal function in dosing decisions.
Overvaluing rare adverse effects instead of common ones.

Practical mini-case

A 58-year-old man with hypertension is started on a new medication. One week later, blood tests show potassium 5.8 mmol/L and creatinine has risen by 20% from baseline. He is asymptomatic.

What drug was started, and what is the most appropriate next step?

Answer: An ACE inhibitor; review contributing factors and repeat blood tests rather than immediate cessation. Explanation: A modest creatinine rise is expected. Hyperkalaemia requires assessment and mitigation, not reflex drug withdrawal.

Practical study checklist

Revise drugs by class, not individually
Pair each class with one key adverse effect and one test
Practise short blocks using Free MRCP MCQs
Consolidate fortnightly with a mock test
Keep a single-page summary for rapid review

FAQs

How detailed should drug side effects revision be for MRCP Part 1?

Focus on common and serious effects with clear monitoring requirements; rare reactions are low yield.

Are monitoring intervals tested?

No—knowing which investigation to check is sufficient.

Do I need to memorise all drug interactions?

Prioritise high-risk drugs such as warfarin and lithium.

Are newer drugs examined?

Yes, but usually through class effects rather than brand-specific details.

What’s the best way to retain this topic?

Repeated MCQs with spaced revision and regular mock tests.

Call to action

Drug side effects and monitoring are among the safest marks in MRCP Part 1. Anchor this topic within your wider revision using the MRCP Part 1 overview, practise actively with the question bank, and stress-test your recall under exam conditions with mock tests.